Nkarta, Inc. (NKTX) Stock Analysis & Investment Frameworks
Nkarta, Inc. (NKTX) stock analysis on Invetso. Review Nkarta, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Nkarta, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Nkarta, Inc. Key Financial Metrics
- Market Cap: $123.91M
- Revenue: $N/A
- ROE: -48.58%
- ROIC: -48.89%
- Dividend Yield: N/A
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta, Inc. Investment Frameworks
Invetso analyzes Nkarta, Inc. (NKTX) across the following frameworks:
- Nkarta, Inc. 10Y Growth Potential
- Nkarta, Inc. Scenario Analysis
- Nkarta, Inc. Risks & Opportunities
- Nkarta, Inc. Economic Moat
- Nkarta, Inc. Business Model
- Nkarta, Inc. Management
- Nkarta, Inc. SWOT Analysis
- Nkarta, Inc. Porter's 5 Forces
- Nkarta, Inc. PESTLE Analysis
- Nkarta, Inc. ESG Analysis